<DOC>
	<DOCNO>NCT03076086</DOCNO>
	<brief_summary>The aim study validate two new biomarkers sputum sample . These PiP3 ( phosphoinositolphospat ) phosphor protein , represent important protein within inflammatory situation lung .</brief_summary>
	<brief_title>Investigation Secreted Phosphoproteins PiP3 ( Phosphoinositolphospat 3 ) Sputum</brief_title>
	<detailed_description>Within study , sputum sample collect 3 repetitive occasion 3 week interval different donor . The objective ass biomarker specificity reproducibility two group ( smoker non-smokers ) . The method measurement shall validate repetitive measurement sputum sample , i.e . comparison multiple measurement sample comparison different sample donor .</detailed_description>
	<criteria>• Healthy male female subject , age 2545 year . Women consider inclusion pregnant , confirm pregnancy test nursing . Females childbearing potential need use highly effective method contraception entire study ( vasectomised partner , sexual abstinence lifestyle female complete abstinence intercourse two week prior first visit least 72 hour last visit , implant , injectables , combine oral contraceptive , hormonal IUDs ( intrauterine device ) doublebarrier method , i.e . double combination IUD , condom spermicidal gel , diaphragm , sponge , cervical cap ) . Body weight ≥ 50 kg BMI ( body mass index ) within range 1932 kg/m² Smokers need consume least ten cigarette per day need least ten packyear Nonsmokers need nonsmoking since least year smoke history 1 packyear . FEV1 ( forced expiratory volume one second ) ≥80 % predict FEV1/FVC ( force expiratory vital capacity ) ≥70 % • History acute infection four week prior inform consent visit . Regular intake medication . Past present disease , judge investigator , may affect outcome study . These disease include , limited , cardiovascular disease , malignancy , hepatic disease , renal disease , hematological disease , neurological disease , endocrine disease pulmonary disease ( include confine chronic bronchitis , emphysema , tuberculosis , bronchiectasis cystic fibrosis ) . Participation another clinical trial 30 day prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>